Nurix Therapeutics, Inc.
- Jurisdiction
United States - ISIN
US67080M1036 (NRIX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. Read full profile
Stock price
Fundamentals
- Net revenue
€75.83M - Gross margin
40.8% - EBIT
-€197.73M - EBIT margin
-260.8% - Net income
-€177.88M - Net margin
-234.6%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Dividends
No dividend payouts
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| van Houte Hans | Chief Financial Officer |
|
|
|
|
| Hansen Gwenn | Chief Scientific Officer |
|
|
|
|
| Ring Christine | Chief Legal Officer |
|
|
|
|
| van Houte Hans | Chief Financial Officer |
|
|
|
|
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Cathie Wood |
|
|
|
Buy |
| Peter Brown |
|
|
|
Sell |